Development and characterization of combination of zidovudine and lamivudine liposomal drug delivery system

Abstract

Zidovudine is an antiretroviral drug with activity against Human Immunodeficiency Virus (HIV) Type 1. Lamivudine

(Epivir-HBV) is used to treat hepatitis B infection. Lamivudine and Zidovudine are nucleoside reverse transcriptase

inhibitors with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Combination of zidovudine and

liposomes were developed by thin film hydration method. Drug and excipient compatibility studies measured by

using FTIR. These liposomes were evaluated for particle size, drug entrapment efficiency, SEM, in vitro drug release

studies and stability studies. Percentage drug entrapment of liposomes was found to be within the range of 65.98-

85.55%. In vitro dissolution was carried out for 8 hours and the percentage drug release for all the formulations was

in the range of 83.56-93.72%. Optimized formulation follows zero order kinetics.